• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail
-

Search Publications



Fields



Centers











Starting Date


Ending Date


Order by

Entry Details

AAPS J 2016 Jul;18(4):1032-8

Clinical, pharmacokinetic, and in vitro studies to support bioequivalence of ophthalmic drug products.

Choi SH, Lionberger RA

Abstract

For ophthalmic drug products, the determination of bioequivalence can be challenging, as drug concentrations at the site of action cannot always be measured. The FDA has recommended a variety of studies that can be used to demonstrate bioequivalence for different ophthalmic drug products. Product-specific bioequivalence recommendations for 28 ophthalmic products have been posted on FDA's website as of May 2016, outlining the specific tests which should be performed to demonstrate bioequivalence. The type of study that can be used to demonstrate bioequivalence depends on the drug product's active pharmaceutical ingredient(s), dosage form, indication, site of action, mechanism of action, and scientific understanding of drug release/drug availability and drug product characteristics. This article outlines the FDA's current guidance on studies to demonstrate bioequivalence through clinical endpoint studies, pharmacokinetic studies, and in vitro studies for generic ophthalmic drug products.


Category: Journal Article
PubMed ID: #27184578 DOI: 10.1208/s12248-016-9932-z
Includes FDA Authors from Scientific Area(s): Drugs
Entry Created: 2016-05-19 Entry Last Modified: 2016-07-31
Feedback
-
-